Latest & greatest articles for simvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on simvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on simvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for simvastatin

61. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals Heart Protection Study Collaborative Group (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of simvastatin (40 mg/day) for the reduction of cardiovascular events was examined. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis

NHS Economic Evaluation Database.2005

62. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial)

Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared (...) with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Miller P S, Smith D G, Jones P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use rosuvastatin (10, 20 or 40 mg) in the treatment of patients

NHS Economic Evaluation Database.2005

63. Effect of splitting simvastatin tablets for control of low-density lipoprotein cholesterol

Effect of splitting simvastatin tablets for control of low-density lipoprotein cholesterol Effect of splitting simvastatin tablets for control of low-density lipoprotein cholesterol Effect of splitting simvastatin tablets for control of low-density lipoprotein cholesterol Parra D, Beckey N P, Raval H S, Schnacky K R, Calabrese V, Coakley R W, Goodhope R C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The therapeutic substitution of split tablets for whole tablets of the same dose of simvastatin was examined. The intervention was applied only to patients receiving a dose of simvastatin that could be achieved by splitting a larger dose in half (i.e. 5, 10, 20 or 40 mg). Type of intervention Secondary prevention. Economic

NHS Economic Evaluation Database.2005

65. Simvastatin reduced mortality and vascular events in diabetes mellitus

Simvastatin reduced mortality and vascular events in diabetes mellitus Simvastatin reduced mortality and vascular events in diabetes mellitus | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Simvastatin reduced mortality and vascular events in diabetes mellitus Article Text Therapeutics Simvastatin reduced mortality and vascular events in diabetes mellitus Free Elizabeth Barrett-Connor , MD Statistics from Altmetric.com No Altmetric data available for this article. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering

Evidence-Based Medicine (Requires free registration)2005

66. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. 16287954 2005 11 18 2005 11 22 2016 10 17 1538-3598 294 19 2005 Nov 16 JAMA JAMA High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. 2437-45 Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than (...) enrolled 8888 patients aged 80 years or younger with a history of acute MI. Patients were randomly assigned to receive a high dose of atorvastatin (80 mg/d; n = 4439), or usual-dose simvastatin (20 mg/d; n = 4449). Occurrence of a major coronary event, defined as coronary death, confirmed nonfatal acute MI, or cardiac arrest with resuscitation. During treatment, mean LDL-C levels were 104 (SE, 0.3) mg/dL in the simvastatin group and 81 (SE, 0.3) mg/dL in the atorvastatin group. A major coronary event

JAMA2005

67. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). 15337403 2004 08 31 2004 09 17 2015 06 16 1474-547X 364 9436 2004 Aug 28-Sep 3 Lancet (London, England) Lancet Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). 771-7 The effects of cholesterol-lowering treatment with statins on mortality and risk of cancer beyond the usual 5-6-year trial periods are unknown. We extended (...) post-trial follow-up of participants in the Scandinavian Simvastatin Survival Study (4S) to investigate cause-specific mortality and incidence of cancer 5 years after closure of the trial. 4S was a randomised double-blind trial of simvastatin or placebo in patients with coronary heart disease, serum total cholesterol 5.5-8.0 mmol/L, and serum triglycerides 2.5 mmol/L or lower. The double-blind period lasted for a median of 5.4 years (range for survivors 4.9-6.3) and ended in 1994. After the trial

Lancet2004

68. Oral simvastatin treatment in relapsing-remitting multiple sclerosis.

Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Many drugs have been approved for relapsing forms of multiple sclerosis but are only partly effective, are injected, and are expensive. We aimed to investigate use of of oral simvastatin (80 mg) in 30 individuals with relapsing-remitting multiple sclerosis. The mean number of gadolinium-enhancing lesions at months 4, 5, and 6 of treatment was compared with the mean number of lesions noted on pretreatment brain MRI scans (...) . Number and volume of Gd-enhancing lesions declined by 44%, (p<0.0001) and 41% (p=0.0018), respectively. Treatment was well tolerated. Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability.

Lancet2004

69. Using a data warehouse to monitor clinical outcomes associated with simvastatin tablet splitting

Using a data warehouse to monitor clinical outcomes associated with simvastatin tablet splitting Using a data warehouse to monitor clinical outcomes associated with simvastatin tablet splitting Using a data warehouse to monitor clinical outcomes associated with simvastatin tablet splitting Coblio N A, Mowrey K A, Ford V, Loos D, McCormick M T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The prescribing of a simvastatin tablet-splitting regimen was compared with the switch from a whole to a simvastatin tablet-splitting regimen. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised all patients taking simvastatin, as obtained from a data

NHS Economic Evaluation Database.2004

70. Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data

Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data Armstrong E P, Zachry W M, Malone D C Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of simvastatin and lovastatin/extended-release niacin to achieve low-density lipoprotein (LDL) and high-density Lipoprotein (HDL) cholesterol goals. The simvastatin pathway started with 20 mg/day and was titrated monthly to a maximum dosage of 80

NHS Economic Evaluation Database.2004

71. Comparing hyperlipidemia control with daily versus twice-weekly simvastatin

Comparing hyperlipidemia control with daily versus twice-weekly simvastatin Comparing hyperlipidemia control with daily versus twice-weekly simvastatin Comparing hyperlipidemia control with daily versus twice-weekly simvastatin Mangin E F, Robles G I, Jones W N, Ford M A, Thomson S P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of statins to control hyperlipidaemia was examined. Patients needing treatment to manage hyperlipidaemia were given either 40 or 80 mg simvastatin twice a week. The comparator treatment was 10 or 20 mg simvastatin daily. Type of intervention Primary and secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised veterans of the US

NHS Economic Evaluation Database.2004

72. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. 15016485 2004 03 12 2004 04 20 2016 12 03 1474-547X 363 9411 2004 Mar 06 Lancet (London, England) Lancet Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. 757-67 Lower blood cholesterol concentrations have (...) consistently been found to be strongly associated with lower risks of coronary disease but not with lower risks of stroke. Despite this observation, previous randomised trials had indicated that cholesterol-lowering statin therapy reduces the risk of stroke, but large-scale prospective confirmation has been needed. 3280 adults with cerebrovascular disease, and an additional 17256 with other occlusive arterial disease or diabetes, were randomly allocated 40 mg simvastatin daily or matching placebo. Subgroup

Lancet2004

73. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. 15337732 2004 09 15 2004 09 21 2016 10 17 1538-3598 292 11 2004 Sep 15 JAMA JAMA Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. 1307-16 Limited data are available evaluating how the timing and intensity of statin therapy following an acute coronary syndrome (ACS) event affect (...) clinical outcome. To compare early initiation of an intensive statin regimen with delayed initiation of a less intensive regimen in patients with ACS. International, randomized, double-blind trial of patients with ACS receiving 40 mg/d of simvastatin for 1 month followed by 80 mg/d thereafter (n = 2265) compared with ACS patients receiving placebo for 4 months followed by 20 mg/d of simvastatin (n = 2232), who were enrolled in phase Z of the A to Z trial between December 29, 1999, and January 6, 2003

JAMA2004

74. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. 12814710 2003 06 19 2003 07 10 2016 12 03 1474-547X 361 9374 2003 Jun 14 Lancet (London, England) Lancet MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. 2005-16 Individuals with diabetes are at increased risk of cardiovascular morbidity and mortality, although (...) simvastatin daily or matching placebo. Prespecified analyses in these prior disease subcategories, and other relevant subcategories, were of first major coronary event (ie, non-fatal myocardial infarction or coronary death) and of first major vascular event (ie, major coronary event, stroke or revascularisation). Analyses were also conducted of subsequent vascular events during the scheduled treatment period. Comparisons are of all simvastatin-allocated versus all placebo-allocated participants (ie

Lancet2003

75. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.

Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. 11829698 2002 02 06 2002 02 19 2016 10 17 0098-7484 287 5 2002 Feb 06 JAMA JAMA Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. 598-605 Limited information exists on the interaction between diet and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and the (...) interaction's effect on serum lipid and lipoprotein levels, insulin sensitivity, and circulating antioxidant vitamin and provitamin levels. To evaluate the separate and combined effects of diet and simvastatin therapy on serum levels of lipids, lipoproteins, antioxidants, and insulin. Randomized, controlled crossover trial conducted from August 1997 to June 1998 in 120 previously untreated hypercholesterolemic men aged 35 to 64 years who were recruited from the community in Turku, southwestern Finland

JAMA2002

76. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. 12114036 2002 07 12 2002 07 23 2016 11 24 0140-6736 360 9326 2002 Jul 06 Lancet (London, England) Lancet MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. 7-22 Throughout the usual LDL cholesterol range in Western populations, lower blood concentrations (...) are associated with lower cardiovascular disease risk. In such populations, therefore, reducing LDL cholesterol may reduce the development of vascular disease, largely irrespective of initial cholesterol concentrations. 20,536 UK adults (aged 40-80 years) with coronary disease, other occlusive arterial disease, or diabetes were randomly allocated to receive 40 mg simvastatin daily (average compliance: 85%) or matching placebo (average non-study statin use: 17%). Analyses are of the first occurrence

Lancet2002

77. Increased National Cholesterol Education Program (NCEP) goal attainment: outcome assessment of Department of Defense conversion to cerivastatin and simvastatin

Increased National Cholesterol Education Program (NCEP) goal attainment: outcome assessment of Department of Defense conversion to cerivastatin and simvastatin Increased National Cholesterol Education Program (NCEP) goal attainment: outcome assessment of Department of Defense conversion to cerivastatin and simvastatin Increased National Cholesterol Education Program (NCEP) goal attainment: outcome assessment of Department of Defense conversion to cerivastatin and simvastatin Beaudoin D, Spaar E (...) , Lowenthal S P, Chung K C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was a mandated statin formulary conversion programme that designated cerivastatin and simvastatin as preferred

NHS Economic Evaluation Database.2001

78. Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol

Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol Ito M K, Lin J C, Morreale A P, Marcus D B, Shabetai R, Dresselhaus T R, Henry R R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of simvastatin to reduce low-density lipoprotein (LDL) cholesterol levels. Type of intervention Primary and secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients receiving pravastatin at a Veterans Affairs medical centre. Setting The setting

NHS Economic Evaluation Database.2001

79. [Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia]

[Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia] Analisis coste-efectividad de atorvastatina frente a simvastatina como tratamiento hipolipemiante en pacientes hipercolesterolemicos en atencion primaria [Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia] Analisis coste-efectividad de atorvastatina frente (...) a simvastatina como tratamiento hipolipemiante en pacientes hipercolesterolemicos en atencion primaria [Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia] Tarraga Lopez P J, Celada Rodriguez A, Cerdan Oliver M, Solera Albero J, Ocana Lopez J M, de Miguel Clave J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary

NHS Economic Evaluation Database.2001

80. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. 11757504 2001 11 19 2001 12 28 2015 11 19 0028-4793 345 22 2001 Nov 29 The New England journal of medicine N. Engl. J. Med. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. 1583-92 Both lipid-modifying therapy and antioxidant vitamins are thought to have benefit in patients with coronary disease. We studied simvastatin-niacin and (...) antioxidant-vitamin therapy, alone and together, for cardiovascular protection in patients with coronary disease and low plasma levels of HDL. In a three-year, double-blind trial, 160 patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels were randomly assigned to receive one of four regimens: simvastatin plus niacin, vitamins, simvastatin-niacin plus antioxidants; or placebos. The end points were arteriographic evidence of a change in coronary stenosis

NEJM2001